BioCentury
ARTICLE | Company News

Kereos, The Dow Chemical Co. deal

September 27, 2004 7:00 AM UTC

DOW granted Kereos exclusive commercialization rights to chelating molecules and chelate technology that Kereos will incorporate into its cancer and cardiovascular imaging agents, KI-0001 and KI-0002,...